EUDA Health Holdings Limited Warrant

EUDA Health Holdings announced that its partner Shenzhen Inno Immune received government approval under the 2025 Shenzhen Key Industry R&D Program to develop TCR-T cell therapies for solid tumors, with potential funding of approximately $434,688. EUDA holds distribution rights for selected immunotherapies in Malaysia through this partnership.

EUDA Health Holdings Limited received a notice from Nasdaq on April 23, 2026, indicating it failed to maintain the required minimum market value of listed securities of $35 million. The company has 180 calendar days until October 20, 2026, to regain compliance by achieving a market value of $35 million or more for at least ten consecutive busines...

EUDA Health Holdings announced a major expansion of its longevity and regenerative medicine strategy by launching a comprehensive stem cell therapy platform and establishing its first clinic in Shenzhen, China. The company is upgrading Shenzhen Inno's cGMP facility to incorporate iPSC technology from GO POSB and Japanese partners, while opening a...